PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50122C00047Chimerix INC: ar&d for smallpox antiviral — Chimerix, Inc

Chimerix, Inc holds $-614,221 across 1 federal awards. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Oct 1, 2028 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Department of Health and Human Services (HHS)

Agency

Chimerix, Inc

Recipient

Oct 1, 2028

PoP end

$213.8M

Obligated

541714

NAICS

AJ15

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

NONE

Contract number75A50122C00047

AgencyDepartment of Health and Human Services (HHS)

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentChimerix, Inc

UEIKLDQF5TYQM45

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAJ15

Place of performanceDURHAM, NC

Related solicitation75A50122R00012

PoP end (current)Oct 1, 2028

PoP end (w/ options)Aug 28, 2032

Obligated$213.8M

CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL is a federal NONE award for Department of Health and Human Services (HHS) held by Chimerix, Inc. Estimated value $213.8M ($213.8M obligated). Current period of performance ends Oct 1, 2028 (potential Aug 28, 2032). Last award drew 1 bidder. Place of performance: DURHAM, NC. Related solicitation 75A50122R00012.

CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL

Recompete timing

Public

● Expiring in 735 days

Current PoP ends Oct 1, 2028 (735 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Apr 1, 2027.

Bonuses end Sept 30

Want the durability read on 75A50122C00047? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Chimerix, Inc — $-614,221 obligated across 1 awards (firm-wide, all agencies).

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50122C00047?

75A50122C00047 (Chimerix INC: ar&d for smallpox antiviral) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $213.8M, currently held by Chimerix, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50122C00047?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50122C00047 to Chimerix, Inc.

Who is the incumbent on 75A50122C00047?

Chimerix, Inc is the incumbent with $-614,221 across 1 related awards in SCOUT’s public footprint. The current period of performance ends Oct 1, 2028.

When does Chimerix, Inc’s 75A50122C00047 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 1, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50122C00047? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Sep 10, 2026 · refreshed monthlyLatest procurement action Jul 8, 2026